GlassScriptPhysician profile
Husam Nazer
NPI 1811178106
$1,133.10
in general payments reported to CMS, 2019-2025
15 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $32.46 · 2023: $452 · 2024: $380 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $312.10 | 2019-2024 | |
| Abbvie INC. | $274.03 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.77 | 2020-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.05 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $48.89 | 2023-2024 | Dificid |
| Astrazeneca Pharmaceuticals LP | $25.31 | 2024 | Andexxa |
| Ferring Pharmaceuticals INC. | $23.15 | 2023 | Rebyota |
| Mallinckrodt Hospital Products INC. | $22.89 | 2024 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $22.62 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $20.88 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $20.44 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $18.83 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.51 | 2023 | Cyltezo |
| Ardelyx, INC. | $16.74 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $14.89 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Nazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.